Company / Capital Expenditures
X4 Pharmaceuticals, Inc Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$60.0K
FY2025
5-year range
$0 / $1.4M
FY2021-FY2025
Trend
-41.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $1M to $60,000 over the past 3 years.
Based on SEC 10-K filings.
$60,000 in FY2025 with a 3-year CAGR of -64.7%.
Declined from $1M to $60,000 over the past 3 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -64.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -64.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 41.7% year-over-year.
- Peak capital expenditures was recorded in FY2022.
- Lowest capital expenditures in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.0K | -41.7% |
| FY2024 | $103.0K | -92.4% |
| FY2022 | $1.4M | +682.8% |
| FY2021 | $174.0K | - |
| FY2020 | $0 | -100.0% |
| FY2018 | $73.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026